In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, ...
Scaling without losing local relevance requires humility, trust, and a willingness to relinquish the illusion that control ...
Edwards Lifesciences withdrew its global anti-copycat policy, prompting European Union antitrust regulators to close an investigation that began with dawn raids back in 2023. The European Commission ...
Disc Medicine received a Complete Response Letter (CRL) from FDA for its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP), delaying a potential ...
Edwards Lifesciences withdrew its global anti-copycat policy, prompting European Union antitrust regulators to close an investigation that began with dawn raids back in 2023. The European Commission ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...
Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...
The EY deals leader discusses recent findings and trends from 2025.
Sanofi appointed Belén Garijo as its new chief executive officer, marking a leadership transition as the company enters its ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results